Biogen and Eisai to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab
Neurimmune Therapeutics AG today announced that, following the successful completion of key research milestones, its lead human therapeutic antibody for Alzheimer’s disease has advanced into preclinical development, triggering milestone payments of an undisclosed amount from Biogen Idec (NASDAQ: BIIB). Neurimmune partnered with Biogen Idec for the worldwide development and commercialization of novel, fully human antibodies for the treatment of Alzheimer’s disease in November 2007. The alliance focuses on the development of antibodies that bind to amyloid beta (Abeta), a pathogenic molecule thought to cause neurodegeneration and loss of cognitive function in Alzheimer’s patients.
«Neurimmune’s unique Reverse Translational Medicine (RTM™) technology platform combined with in-depth expertise in neuroscience played a critical role in moving the program forward. The fact that we could reach all preclinical milestones in such a short period of time shows that our RTM™ technology can significantly accelerate the transition from discovery to development of human monoclonal antibodies,» said Jan Grimm, Chief Scientific Officer of Neurimmune Therapeutics.
«The rapid advancement into preclinical development demonstrates the progress and productivity of our collaboration with Biogen Idec – we are very happy to work with a partner that has such extensive and valuable experience in the development of biopharmaceuticals. The significant milestone payments also provide Neurimmune with additional financial stability to support the sustainable future development of our company,» said Michael Salzmann, COO and General Manager of Neurimmune Therapeutics.
«Biogen Idec is globally recognized as a leader in the development of innovative therapies for neurologic diseases, and this program is an important entry into Alzheimer’s disease for us,» said Kenneth Rhodes, PhD, Vice President, Discovery Neurobiology, Biogen Idec. «The rapid progression of this antibody is the result of a very effective joint collaboration, which capitalized on Neurimmune’s novel RTM™ approach and our proven expertise in neuroscience and the development of therapeutic antibodies.»
Alzheimer’s disease is the most prevalent age-related neurodegenerative disease affecting more than 15 million patients worldwide. There are currently no treatments approved to slow or stop the progression of the disease. Patients with Alzheimer’s disease experience the progressive loss of cognitive functions, particularly those related to memory, followed by death eight to 15 years after a progressive decline in their disease. The pathology of Alzheimer’s disease is characterized by distinctive features, including the deposition of Abeta in the form of senile plaques and the loss of specific neuronal populations in the brain.
Neurimmune Therapeutics AG is a Swiss biotechnology company dedicated to the identification of novel therapeutics for the treatment of human diseases with a focus on neurodegenerative disorders such as Alzheimer’s disease. Based on novel scientific concepts developed at the University of Zurich, Neurimmune Therapeutics has established a unique technology platform – RTM™ (Reverse Translational Medicine) – that supports Neurimmune Therapeutics’ translational research-focused drug discovery programs.
Neurimmune Therapeutics’ business strategy focuses on the discovery and development of human-derived antibodies through RTM™ at an early stage of the pharmaceutical value chain and partnering product candidates targeting significant markets and unmet medical needs with leading biopharmaceutical companies for later-stage development and marketing.
Biogen and Eisai to discontinue Phase 3 ENGAGE and EMERGE trials of Aducanumab
Neurimmune-led research consortium receives Target ALS discovery grant
NovaGo Therapeutics raises CHF 10 million to develop regenerative anti-Nogo therapy for stroke
Neurimmune appoints John Dellapa as General Counsel
Neurimmune announces publication in Science Translational Medicine
Neurimmune appoints Natascha Schill as VP Project & Alliance Management
Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Neurimmune Achieves Milestone in Collaboration with Ono Pharmaceutical
Neurimmune appoints Christoph Hock as Chief Medical Officer to lead clinical development
Biogen and Eisai report data from long-term extension Phase 1b study of investigational Alzheimer's disease treatment Aducanumab
Michael Salzmann honored as Corporate Professional of the Year by The M&A Advisor
Biogen and Neurimmune Announce Option Exercise for Alzheimer’s Disease Investigational Treatment Aducanumab
Neurimmune announces additional collaboration with Biogen on human-derived antibodies for neurodegenerative diseases
Neurimmune appoints Fabian Buller as Chief Business Officer
In January 2018, Biogen dosed the first patient in the Phase 2 SPARK study of BIIB054 (anti-alpha-synuclein antibody) in Parkinson's disease.
Neurimmune Announces Collaboration with Ono Pharmaceutical in Neurodegenerative Diseases Field
Neurimmune Raises $150 Million to Finance its Growth Strategy
Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
BIIB076 Moves into Phase 1 for Alzheimer's Disease
Neurimmune's joint research project with University of Zurich awarded Pfizer Research Prize 2017.
Foreign Policy magazine recognized Neurimmune's president Roger Nitsch among the 100 Leading Global Thinkers 2016
Biogen Presents Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimer’s Disease Meeting
Neurimmune and TVM Capital Life Science Announce Creation of AL-S Pharma to Develop Innovative Therapy for Patients with ALS
Aducanumab Granted FDA Fast Track Designation and Recent Interim Analysis from PRIME Consistent with Results Previously Reported
Early Results Show Aducanumab Removes Amyloid Plaques in Patients with Alzheimer's Disease
Aducanumab accepted into EMA's PRIME Program
BIIB076 (anti-tau mAb) moving into pre-IND toxicology studies
Neurimmune’s data on its broadly neutralizing human monoclonal JC polyomavirus VP1–specific antibodies as candidate therapeutics for PML published in Science Translational Medicine
Roger Nitsch honored at Alzheimer's translation and therapeutic panel and luncheon by the American Federation for Aging Research (AFAR)
Neurimmune Receives Major Development Milestone upon Initation of Global Phase 3 Studies with Aducanumab for Early Alzheimer’s Disease
Ramot at Tel Aviv University Ltd. and Neurimmune Announce Sponsored Research Agreement for Alzheimer's Disease Treatment
Biogen Presents New Data from Phase 1B Study of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) at Alzheimer’s Association International Conference® 2015
BIIB054 reached significant milestone
Biogen Idec Presents Positive Interim Results from Phase 1b Study at 2015 AD/PD Conference
Aducanumab (BIIB037) showed significant time and dose dependent reduction of beta amyloid in the brain of AD patients
Christoph Hock nominated as VP at the University of Zurich
Aducanumab (BIIB037) for the treatment of Alzheimer’s disease reduced brain beta-amyloid levels in a Phase 1b trial
ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS
Human-Derived SOD1 Antibodies Show Promise in ALS Mice
Biogen presents the first clinical data from an ongoing Phase 1 study of BIIB037 in mild to moderate Alzheimer’s
Biogen Idec began a double-blind, placebo-controlled Phase Ib trial
Neurimmune acquires USD 1.9m funding from Swiss CTI
Biogen Idec submitted an investigational new drug (IND) application
Neurimmune introduced BIIB037
Biogen Idec and Neurimmune announce agreement on three neurodegenerative disease programs
Neurimmune awarded the 2010 ZKB TECHNOPARK® Pioneer Award
Neurimmune Therapeutics Announces Advancement of Alzheimer's Program into Preclinical Development
New facility at the Bio-Technopark Zurich in Schlieren
Biogen Idec and Neurimmune Therapeutics announce alliance to develop treatments for Alzheimer’s disease